H2020Индивидуална стипендия2020–2022

MANTIS · Understanding the impact of DNA demethylation in Motor Neuron Disorders

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2020-07-01 → 2022-10-20
Финансиране от ЕС
196 708 €
Участници
1
Схема
MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Болестите на моторните неврони, като СМА и АЛС, се изследват чрез анализ на промените в ДНК метилирането, които влияят върху работата на гените. Разбирането на тези процеси помага при търсенето на нови цели за лечение на тези тежки състояния.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Understanding the impact of DNA demethylation in Motor Neuron Disorders

The primary focus of this research is on motor neuron disorders (MND), including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). These disorders are severe, with a major symptom being the degeneration of motor neurons. Motor neurons are essential for the central nervous system, responsible for transmitting signals from the brain to muscles throughout the body. When these neurons degenerate or die, it leads to muscle weakness, paralysis, and eventually can be life-threatening. A significant aspect of this MANTIS project is the investigation of DNA methylation, a biological process where a methyl group (a specific chemical structure) is added to DNA. This process significantly affects gene expression without changing the actual DNA sequence. In the context of MND, alterations in DNA methylation patterns have been observed, but the exact role and mechanisms of these changes are not well understood. Understanding these epigenetic changes (changes in gene expression caused by factors other than changes in the DNA sequence) is crucial because they could be key drivers in the progression of these diseases or potential targets for treatment. The importance of this research for society cannot be understated. SMA and ALS, as part of MNDs, pose significant challenges not only to the individuals directly affected but also to their families, healthcare systems, and society at large. These diseases often lead to a rapid decline in the quality of life, as patients lose their ability to perform everyday tasks and become increasingly dependent on others. This results also in substantial economic burdens due to medical costs and loss of productivity. Moreover, these diseases currently have limited treatment options. In the case of SMA, the currently approved treatment achieves survival milestone but complete muscle function restoration remains limited. Understanding the underlying mechanisms, especially the role of DNA methylation in these diseases, could pave the way for the development of new, more effective treatments. The project has several ambitious but crucial objectives centered on understanding and potentially manipulating the process of DNA methylation to treat or prevent MNDs. Firstly, the project aims to define precisely how DNA methylation and demethylation regulate gene expression in SMA. This involves mapping the specific changes in DNA methylation patterns and understanding how these changes affect the functioning of genes involved in motor neuron health and survival. By identifying these patterns, researchers hope to pinpoint specific genes or pathways that could be targeted in treatments. Secondly, the research focuses on the role of TET enzymes, which are involved in converting methylated cytosines (5mC) in DNA to hydroxymethylated cytosines (5hmC), a change that can influence gene expression. The interaction of these enzymes with motor neuron pathology, specifically in relation to the Survival of Motor Neuron (SMN1) protein, is of particular interest. SMN1 is crucial in SMA, as its deficiency leads to motor neuron death. Understanding how TET enzymes interact with SMN1 could reveal new therapeutic targets or strategies. Finally, the project seeks to establish the potential of using targeted demethylation as a therapeutic strategy. This involves using advanced technologies like CRISPR/Cas9 to specifically alter DNA methylation at targeted genomic locations. The goal is to reverse or correct the disease-related epigenetic profiles, potentially restoring normal gene function and rescuing motor neuron health.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Motor neuron disorders (MND) are a spectrum of devastating diseases caused by motor neuron (MN) cell death. Recent findings revealed that DNA methylation is a hallmark of MN cell death. However, the cause and affected mechanisms leading to methylation increase remain mostly unknown, therefore limiting the design of therapeutic intervention. The discovery of a novel DNA modification has provided a paradigm shift in the understanding of DNA methylation and demethylation regulatory network. In fact, methylated cytosines (5mC) can be converted to hydroxymethylated cytosines (5hmC) by Ten-eleven-translocation (TET) enzyme family. 5hmC is found to be stably present in DNA and to influence gene expression as an epigenetic mark independent of 5mC. My preliminary experiments showed that MN death in a severe mouse model of Spinal Muscular Atrophy (SMA) is correlated to a genome-wide increase in 5mC levels and loss of 5hmC. This research proposal therefore aims to define the role of 5hmC and the TET family of enzymes in controlling MN pathophysiology. To address the common role of DNA demethylation loss in MND, I will investigate the methylation mechanism in SMA and another MND- Amyotrophic lateral sclerosis (ALS). The specific aims of this project are to (1) define the exact profile of 5mC and 5hmC in regulating gene expression in SMA and ALS via a genome-wide reduced representation sequencing; (2) test whether TETs interact with the Survival of Motor Neuron (SMN1) protein that is responsible for MNs cell death in SMA; (3) establish the therapeutic potential of a locus-specific demethylation in promoting restoration of the diseased epigenetic profile using the Crispr/Cas9 technology. These studies will greatly advance the understanding of the epigenetic regulation of MN cell death by 5hmC and TET proteins, and will set the stage for testing the therapeutic potential of these novel regulators in MNs disorders.

Оригинален текст от CORDIS (на английски).

Участници

  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisКоординаторФранция

Връзки

Данни: CORDIS, © Европейски съюз